From Wikipedia, the free encyclopedia
|type=
vaccine/combo/mab/blank
|
Infobox drug/sandbox (edit · t · history · diff · links · /test · Source · e · t · hist · links · /subpages · /doc · /doc edit)
- /testcases2 -- titles, licence, EMA
- /testcases3 -- pregcat, legal, licence, PLLR, ATC; Wikidata
- /testcases4 -- chem formula, mab
- /testcases5 -- identifiers, second id's
- /testcases6 -- all up
- /testcases7images -- images
- /testcases8 -- type, titles
- /testcases9 -- order variants, container_only
- /testcases10 -- pharmacokinetic, localINN (2017) has (data page) -- is a redirect
- /testcases11 -- hormone, gene therapy (2018), has (data page)
- /testcases-FDA -- FDA 2023
- /testcases-warning -- warning box(es)
|
all/check[edit]
- Purge mab = data10; source=data11, target=data12 (freetext)
mab, source
|
| mab = Whole antibody
| fab = [[Fab fragment]]
| f(ab')2 = [[F(ab')2 fragment|F(ab')<sub>2</sub> fragment]]
| fab' = [[Fab' fragment]]
| scfv = [[Single-chain variable fragment]]
| discfv = Di-[[single-chain variable fragment]]
| sdab = [[Single domain antibody]]
| 3funct = [[Trifunctional antibody]]
| clfab = [[Chemically linked Fab]]
| bite = [[Bi-specific T-cell engager]]
| ?
- if mab= then use source=
| label11 = [[Monoclonal antibody#Production|Source]]
| data11 = {{#ifeq: {{{type|}}} | mab | {{#switch: {{lc:{{{source|}}}}}
| =
| a = [[Rat]]
| e = [[Hamster]]
| i = [[Primate]]
| o = [[Mouse]]
| u = [[Human]]
| xi/a = [[chimeric antibody|Chimeric]] ([[rat]]/[[human]])
| xi/e = [[chimeric antibody|Chimeric]] ([[hamster]]/[[human]])
| xi/i = [[chimeric antibody|Chimeric]] ([[primate]]/[[human]])
| xi/o = [[chimeric antibody|Chimeric]] ([[mouse]]/[[human]])
| xi = [[chimeric antibody|Chimeric]]
| zu/a = [[Humanized]] (from [[rat]])
| zu/e = [[Humanized]] (from [[hamster]])
| zu/i = [[Humanized]] (from [[primate]])
| zu/o = [[Humanized]] (from [[mouse]])
| zu = [[Humanized]]
| xizu/a = [[chimeric antibody|Chimeric]]/[[humanized]] hybrid ([[rat]]/[[human]])
| xizu/e = [[chimeric antibody|Chimeric]]/[[humanized]] hybrid ([[hamster]]/[[human]])
| xizu/i = [[chimeric antibody|Chimeric]]/[[humanized]] hybrid ([[primate]]/[[human]])
| xizu/o = [[chimeric antibody|Chimeric]]/[[humanized]] hybrid ([[mouse]]/[[human]])
| xizu = [[chimeric antibody|Chimeric]]/[[humanized]] hybrid
| axo = [[Rat]]/[[mouse]] hybrid
| {{{source|}}} [[:Category:Drugboxes with unformatted antibody source]]
|
vaccine[edit]
|vaccin_type=
|killed |inactivated = Killed/Inactivated
|attenuated = [[Attenuated virus]]
|live = Live bacteria
|toxoid = [[Toxoid]]
|subunit = Subunit
|protein subunit |protein = [[Protein subunit]]
|conjugate=[[Conjugate vaccine]]
|recombinant = [[Recombinant DNA|Recombinant Vector]]
|dna = [[DNA vaccination]]
| ?
TITLE tests (drug_name, INN)[edit]
Licence[edit]
Purge
Side by side comparison{{Infobox drug}} | {{Infobox drug/sandbox}} |
---|
Infobox drug/testcases8 INN: Linezolid | | |
Pronunciation | |
---|
Trade names | Linospan, Zyvox, Zyvoxam, Zyvoxid |
---|
Other names | Lenzomore |
---|
AHFS/Drugs.com | Monograph |
---|
MedlinePlus | a602004 |
---|
License data |
|
---|
Pregnancy category | |
---|
Dependence liability | High |
---|
Addiction liability | Low |
---|
Routes of administration | Intravenous infusion, oral |
---|
ATC code | |
---|
|
Bioavailability | ~100% (oral) |
---|
Protein binding | Low (31%) |
---|
Metabolism | Hepatic (50–70%, CYP not involved) |
---|
Metabolites | some stuff |
---|
Onset of action | 1 hr |
---|
Elimination half-life | 4.2–5.4 hours (shorter in children) |
---|
Duration of action | 1 to 3 hr |
---|
Excretion | Nonrenal, renal, and fecal |
---|
|
(S)-N-({3-[3-fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide
| CAS Number | |
---|
PubChem CID | |
---|
IUPHAR/BPS | |
---|
DrugBank | |
---|
ChemSpider | |
---|
UNII | |
---|
KEGG | |
---|
ChEMBL | |
---|
NIAID ChemDB | |
---|
PDB ligand | |
---|
|
Formula | C16H20FN3O4 |
---|
Molar mass | 337.346 g/mol g·mol−1 |
---|
3D model (JSmol) | |
---|
Density | 1.40 g/cm3 |
---|
Melting point | 135 °C (275 °F) |
---|
Boiling point | 140 °C (284 °F) (decomposes) |
---|
Solubility in water | 3 mg/mL (20 °C) |
---|
O=C1O[C@@H](CNC(=O)C)CN1c3cc(F)c(N2CCOCC2)cc3
|
InChI=1S/C16H20FN3O4/c1-11(21)18-9-13-10-20(16(22)24-13)12-2-3-15(14(17)8-12)19-4-6-23-7-5-19/h2-3,8,13H,4-7,9-10H2,1H3,(H,18,21)/t13-/m0/s1 YKey:TYZROVQLWOKYKF-ZDUSSCGKSA-N Y
| NY (what is this?) (verify) | |
Infobox drug/testcases8 INN: Linezolid | | |
Pronunciation | |
---|
Trade names | Linospan, Zyvox, Zyvoxam, Zyvoxid |
---|
Other names | Lenzomore |
---|
AHFS/Drugs.com | Monograph |
---|
MedlinePlus | a602004 |
---|
License data |
|
---|
Pregnancy category | |
---|
Dependence liability | High |
---|
Addiction liability | Low |
---|
Routes of administration | Intravenous infusion, oral |
---|
ATC code | |
---|
|
Bioavailability | ~100% (oral) |
---|
Protein binding | Low (31%) |
---|
Metabolism | Hepatic (50–70%, CYP not involved) |
---|
Metabolites | some stuff |
---|
Onset of action | 1 hr |
---|
Elimination half-life | 4.2–5.4 hours (shorter in children) |
---|
Duration of action | 1 to 3 hr |
---|
Excretion | Nonrenal, renal, and fecal |
---|
|
(S)-N-({3-[3-fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide
| CAS Number | |
---|
PubChem CID | |
---|
IUPHAR/BPS | |
---|
DrugBank | |
---|
ChemSpider | |
---|
UNII | |
---|
KEGG | |
---|
ChEMBL | |
---|
NIAID ChemDB | |
---|
PDB ligand | |
---|
|
Formula | C16H20FN3O4 |
---|
Molar mass | 337.346 g/mol g·mol−1 |
---|
3D model (JSmol) | |
---|
Density | 1.40 g/cm3 |
---|
Melting point | 135 °C (275 °F) |
---|
Boiling point | 140 °C (284 °F) (decomposes) |
---|
Solubility in water | 3 mg/mL (20 °C) |
---|
O=C1O[C@@H](CNC(=O)C)CN1c3cc(F)c(N2CCOCC2)cc3
|
InChI=1S/C16H20FN3O4/c1-11(21)18-9-13-10-20(16(22)24-13)12-2-3-15(14(17)8-12)19-4-6-23-7-5-19/h2-3,8,13H,4-7,9-10H2,1H3,(H,18,21)/t13-/m0/s1 YKey:TYZROVQLWOKYKF-ZDUSSCGKSA-N Y
| NY (what is this?) (verify) | |
Purge
English language variants: Licence or License[edit]
- See also WP:ENGVAR: english language variant of the article
- In {{Infobox drug}}: spelling of licence/license. Default is to be en-US: License.
- Use new parameter
|engvar=
for non-default spelling:
- Default licenSe (US)
|engvar=en-US
licenSe
|engvar=en-UK
licenCe
|engvar=en-NZ
licenCe
Titletests[edit]
The infobox title is a logical result of input:
- {{PAGENAME}} (default)
|drug_name=
(overwrites, eg when PAGENAME is not the INN drugname)
|INN=
(added, when PAGENAME/drug_name is not the INN name)
- See Category:Infobox drug articles with non-default infobox title (779)
Purge (reduced infobox)
- Current infobox title: Diamorphine (INN)
- The new situation required an edit.
Side by side comparison{{Infobox drug}} | {{Infobox drug/sandbox}} |
---|
Heroin INN: Diamorphine | | |
Pronunciation | |
---|
Other names | Diamorphine, Diacetylmorphine, Acetomorphine, (Dual) Acetylated morphine, Morphine diacetate |
---|
AHFS/Drugs.com | heroin |
---|
Dependence liability | Physical: Very high Psychological: Very high |
---|
Addiction liability | Very high |
---|
Routes of administration | Inhalation, transmucosal, intravenous, oral, intranasal, rectal, intramuscular |
---|
ATC code | |
---|
|
Legal status |
- AU: S9 (Prohibited substance)
|
---|
|
(5α,6α)-7,8-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol diacetate
| CAS Number | |
---|
PubChem CID | |
---|
DrugBank | |
---|
ChemSpider | |
---|
UNII | |
---|
ChEBI | |
---|
ChEMBL | |
---|
|
Formula | C21H23NO5 |
---|
Molar mass | 369.41 g/mol g·mol−1 |
---|
|
Heroin INN: Diamorphine | | |
Pronunciation | |
---|
Other names | Diamorphine, Diacetylmorphine, Acetomorphine, (Dual) Acetylated morphine, Morphine diacetate |
---|
AHFS/Drugs.com | heroin |
---|
Dependence liability | Physical: Very high Psychological: Very high |
---|
Addiction liability | Very high |
---|
Routes of administration | Inhalation, transmucosal, intravenous, oral, intranasal, rectal, intramuscular |
---|
ATC code | |
---|
|
Legal status |
- AU: S9 (Prohibited substance)
|
---|
|
(5α,6α)-7,8-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol diacetate
| CAS Number | |
---|
PubChem CID | |
---|
DrugBank | |
---|
ChemSpider | |
---|
UNII | |
---|
ChEBI | |
---|
ChEMBL | |
---|
|
Formula | C21H23NO5 |
---|
Molar mass | 369.41 g/mol g·mol−1 |
---|
|
Lysergide (LSD)[edit]
Purge Reduced infobox.
- Current infobox title: Lysergic acid diethylamide (pagename, not INN)
- New situation would be (adding "(LSD)" is just a liberty I took, to help our readers):
Side by side comparison{{Infobox drug}} | {{Infobox drug/sandbox}} |
---|
Lysergic acid diethylamide (LSD) INN: Lysergide | |
Other names | Acid, LSD, lysergide |
---|
Dependence liability | Low |
---|
Addiction liability | None |
---|
Routes of administration | Oral, etc |
---|
ATC code | |
---|
|
Legal status |
|
---|
|
Metabolism | Hepatic |
---|
Elimination half-life | 3–5 hours |
---|
Excretion | Renal |
---|
|
(6aR,9R)-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]quinoline-9-carboxamide
| CAS Number | |
---|
PubChem CID | |
---|
IUPHAR/BPS | |
---|
DrugBank | |
---|
ChemSpider | |
---|
UNII | |
---|
ChEBI | |
---|
ChEMBL | |
---|
|
Formula | C20H25N3O |
---|
Molar mass | 323.440 g·mol−1 |
---|
|
Lysergic acid diethylamide (LSD) INN: Lysergide | |
Other names | Acid, LSD, lysergide |
---|
Dependence liability | Low |
---|
Addiction liability | None |
---|
Routes of administration | Oral, etc |
---|
ATC code | |
---|
|
Legal status |
|
---|
|
Metabolism | Hepatic |
---|
Elimination half-life | 3–5 hours |
---|
Excretion | Renal |
---|
|
(6aR,9R)-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]quinoline-9-carboxamide
| CAS Number | |
---|
PubChem CID | |
---|
IUPHAR/BPS | |
---|
DrugBank | |
---|
ChemSpider | |
---|
UNII | |
---|
ChEBI | |
---|
ChEMBL | |
---|
|
Formula | C20H25N3O |
---|
Molar mass | 323.440 g·mol−1 |
---|
|
(regular)[edit]
- No need to use
|INN=
. Note the titletext (mousehover).
INN=none[edit]
INN=sense[edit]
INN='none'[edit]
Side by side comparison{{Infobox drug}} | {{Infobox drug/sandbox}} |
---|
|
The time allocated for running scripts has expired.The time allocated for running scripts has expired. |
The time allocated for running scripts has expired.
The time allocated for running scripts has expired.
The time allocated for running scripts has expired.
The time allocated for running scripts has expired.
The time allocated for running scripts has expired.